drug pricing

What were the top selling prescription drugs last year? What segment of the population is most increasing its drug intake? What are the projections of medication spending in the next five years? The answers were just published and will be addressed here.

A new report “produced independently by the QuintilesIMS Institute as a public service, without industry or government funding” reviewed 2016 medicine use and spending in the United States and provides an outlook through 2021. Among their in-depth analysis includes trends in medicine usage, out-of-pocket costs along with spending and growth dynamics. 

With an ever...

It is Game On! at Commissioner Scott Gottlieb's U.S. Food and Drug Administration.

Recognizing the FDA lacks a direct role in drug pricing, his overarching strategy is to facilitate increasing market competition so as to drive down prices-- thereby increasing accessibility and innovation (see details of his Drug Competition Action Plan here). His parallel focus to achieve these goals is to curb abuses of the Orphan Drug Act (ODA). 

President Reagan signed the Orphan Drug Act in 1983 in an attempt to incentivize discovery. Smaller population ...

The cancer drug business is quite a profitable one. A “high risk, high reward” proposition has been the narrative for those in research and development (R&D). Successes, marketing, patent protection and discovery cost money. Failures cost money. Not pursuing a different path with a failure or even a success costs money. As does lost revenue while performing R&D. 

Can an accurate dollar value even be placed on what it takes from idea conception through utilization to develop a new drug? Due to the opaque nature of the industry’s disclosures, a new study published in JAMA Internal Medicine sought to quantify a standard amount by focusing on new cancer drugs and analyzing the...